Anavex Life Sciences (NASDAQ:AVXL) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02), Bloomberg Earnings reports.
Shares of Anavex Life Sciences (AVXL) opened at $3.30 on Tuesday. Anavex Life Sciences has a 12-month low of $3.01 and a 12-month high of $6.64.
AVXL has been the topic of a number of recent research reports. Zacks Investment Research cut Anavex Life Sciences from a “buy” rating to a “hold” rating in a report on Friday, August 18th. ValuEngine cut Anavex Life Sciences from a “hold” rating to a “sell” rating in a report on Thursday, September 28th. Noble Financial reiterated a “buy” rating and issued a $15.00 target price on shares of Anavex Life Sciences in a report on Friday, September 29th. Finally, Maxim Group set a $15.00 target price on Anavex Life Sciences and gave the stock a “buy” rating in a report on Thursday, October 12th.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.